Liver Fibrosis - Modern Methods of Diagnostics and Drug Correction
Abstract
Liver fibrosis is a local or diffuse increase in the amount of connective tissue, extracellular matrix (collagen fibrous tissue in the perisinusoidal space) and the main pathway for the progression of chronic diffuse liver diseases. In the early stages of fibrosis, clinical manifestations are absent, and only a histological examination of a biopsy specimen reveals an excessive accumulation of connective tissue. In the future, fibrosis leads to the formation of nodes of regenerates, vascular anastomoses - to the formation of cirrhosis of the liver
References
Ivashkin V.T., Mayevskaya M.V. Treatment of complications of liver cirrhosis. M., 2011.64 p.
F.E.Nurbaev, F.Kh.Umarov, Sh.T.YuldashovaThe effect of various hepatoprotectors on pathological syndromes in chronic liver diseases and determination of the specific gravity of drug groups / Middle European scientific bulletin; 2020 11; 6 31-34p
George S., Bacon B., Brunt E. et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 Patients. Hepatology 2009;49:729–38p.
Pavlov Ch.S., Zolotarevsky V.B., Tomkevich M.S. Possibility of reversibility of liver cirrhosis. Ross. journalofgastroenterology, hepatologyandcoloproctology. 2006; 1: 20-9.
Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 2007; 117(3):539–48.
Bosch J., Berzigotti A., Garcia-Pagan J.C., Abraldes J.G. The management of portal hypertension: Rational basis, available treatment and future options. J. Hepatol. 2008;48:68–93.
Pavlov Ch.S., Ivashkin VT, ShulpekovaYu.O., Zolotarevsky VB Modern concepts of the pathogenesis, diagnosis and treatment of liver fibrosis. Russianjournalofgastroenterology, hepatology, coloproctology.2005;2(XV):13–20.
Friedman S. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Prac. Gastroenterol. Hepatol. 2004;1:98–105.
Sherlock S., Dooley J. Заболевания печени и желчных путей: A practicalguide. М., 2002. 864p.
Parsons C.J., Takashima M., Rippe R.A. Molecular mechanisms of hepatic fibrogenesis. J GastroenterolHepatol. 2007;22(1):79–84.
Storozhakov G.I., Ivkova A.N. Pathogenetic aspects of fibrogenesis in chronic liver diseases. Wedge. perspectivesofgastroenterology, hepatology. 2009; 2: 3-10.
ShulpekovaYu.O., Ivashkin VT, Mamaev S.N. et al. The level of transforming growth factor-1b (TGF-1b) in blood serum and indicators of cellular immunity in patients with chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology No. 1. T. XI. Appendix No. 12 / Materials of the Sixth Russian Conference "Hepatology Today" 20–23.03. 2003. M., p 14.
Baroni G.S., D’Ambrosio L., Curto P., Casini A., et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology. 1996;23:1189–99.
Iloeje U., Yang H., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130:678–86.
Poynard T., Zoulim F., Ratziu V., et al. Longitudinal assessment of histology surrogate markers (FibroTest–ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am. J. Gastroenterol. 200;100:1970–80.
Pavlov Ch.S., Glushenkov D.V., Ivashkin V.T. Modern possibilities of elastometry, fibro- and acti-test in the diagnosis of liver fibrosis. Russianjournalofgastroenterology, hepatologyandcoloproctology. 2008; 4: 43-52.
Ogawa E., Furusyo N., Toyoda K., et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with withpegylated interferon alpha-2d and ribavirin. Antiviral Res. 2009; 83(2):127–34.
Pavlov Ch.S., Ivashkin V.T. Liver biopsy: methodology and practice today. Russianjournalofgastroenterology, hepatology, coloproctology. 2006; XVI (4): 65–78.
Cadranel J., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nation-wide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477–81.
Gilmore I., Burroughs A., Murray-Lyon I., et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437–41.
Knodell R., Ishak K., Black W., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;4:431–35.
Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995;2:696–99.
Северов М.В.Обратимость фиброза и цирроза печени при HCV-инфекции. Гепатологический форум. 2008;1:2–6.
Lai C., Gane E., Liaw Y., etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007;35:2576–88.
Lai C., Shouval D., Lok A., et al. Entecavirversus lamivudine for patients with HBeAg negative chronic hepatitis B. N. Engl. J. Med. 2006;354:1011–20.
Mallet V., Gilgenkrantz H., Serpaggi J., et al. Brief Communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 2008;149(6):399–403.
Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005;115(2):209–18.
Rockey D.C. Antifibrotic therapy in chronic liver disease Clin. Gastroenterol. Hepatol. 2005;3:95–107.
Zois C., Baltayiannis G., Karayiannis P., Tsianos E. Systematic review: hepatic fibrosis – regression with therapy. Aliment. Pharmacol. Ther. 2008;28:1175–87с
S.N. Mekhtiev, V.V. Stepanenko, E.N. Zinovieva, O.A. Mehdiyeva / Modern concepts of liver fibrosis and methods of its correction / Pharmateca 2014; 6: 80-87p
